Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin.
Open Access
- 15 January 1992
- journal article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 116 (2) , 489-497
- https://doi.org/10.1083/jcb.116.2.489
Abstract
It has been shown that the alpha 4 beta 1 integrin is the lymphocyte receptor for the carboxy terminal cell-binding domain of fibronectin which comprises adhesion sites in Hep 2 and a high affinity site, CS-1, in the type III connecting segment or V (for variable) region. In the present studies, using a series of peptides derived from CS-1, we identify the tripeptide leu-asp-val (LDV), as the minimal peptide capable of supporting stable lymphocyte or melanoma cell adhesion. However, only cells which expressed an active form of the alpha 4 beta 1 complex were capable of attaching to and spreading on LDV peptide. On a molar basis, LDV minimal peptides were either not active or 10-20 times less active than intact CS-1 in promoting the adhesion of lymphocytes expressing the resting form of the receptor. In cells which express the high avidity form of the receptor, LDV and CS-1 were equally effective in promoting cell adhesion and spreading. The avidity of the alpha 4 beta 1 complex could be altered with mAbs to beta 1 which specifically activate beta 1 dependent function. The high avidity form of the alpha 4 beta 1 complex could be induced on U937 cells, T, and B lymphoblastoid cell lines, or PHA-stimulated T cell blasts. Resting PBL could not be induced to bind LDV peptide conjugates by activating antibodies to beta 1 implying that two signals are required for LDV recognition by T cells. In conclusion, these data show clearly that the minimal peptide for the alpha 4 beta 1 complex in CS-1 is the LDV sequence. Although numerous cell populations can interact with intact CS-1 only cells which express an active alpha 4 beta 1 complex can bind the LDV sequence. This implies that cell interaction with the carboxy terminal cell-binding domain of fibronectin can be regulated at several levels: (a) alpha 4 beta 1 expression; (b) activation of the alpha 4 beta 1 complex; and (c) alternate splicing of CS-1 into V+ isoforms of fibronectin.Keywords
This publication has 25 references indexed in Scilit:
- The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valineJournal of Biological Chemistry, 1991
- Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1.Journal of Biological Chemistry, 1990
- Lymphoid cells recognize an alternatively spliced segment of fibronectin via the integrin receptor α4β1Cell, 1990
- Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.The Journal of cell biology, 1989
- The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoproteins Ic-IIa.The Journal of cell biology, 1988
- Adhesion of lymphoid cell lines to fibronectin-coated substratum: Biochemical and physiological characterization and the identification of a 140-kDa fibronectin receptorExperimental Cell Research, 1987
- Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote cell type-specific adhesion.Journal of Biological Chemistry, 1987
- Cell-type-specific fibronectin subunits generated by alternative splicing.Journal of Biological Chemistry, 1986
- Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene.The EMBO Journal, 1985
- Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptorCell, 1985